{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:10:55Z","timestamp":1784740255836,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13555-026-01662-9","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:47:02Z","timestamp":1771235222000},"page":"1675-1692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200\u00a0mg, Risankizumab, and Guselkumab\u2014IL PSO (Italian Landscape Psoriasis)"],"prefix":"10.1007","volume":"16","author":[{"given":"Emanuele","family":"Trovato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cartocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Macagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Campoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Lora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Gioacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Marco","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Satolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pagnanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Michelerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Dragotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-0839","authenticated-orcid":false,"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bianchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Italian Landscape Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Manfredini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Rongioletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santo","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo Lazzaro","family":"Danzuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Altomare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Giofre\u2019","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Scuderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Brunasso","family":"Vannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Di Lernia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fiorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Capo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"19","key":"1662_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"issue":"1","key":"1662_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/ijms19010179","volume":"19","author":"A Chiricozzi","year":"2018","unstructured":"Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018;19(1):179. https:\/\/doi.org\/10.3390\/ijms19010179.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1662_CR3","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/14712598.2022.2093106","volume":"22","author":"E Trovato","year":"2022","unstructured":"Trovato E, Rubegni P, Prignano F. Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome. Expert Opin Biol Ther. 2022;22(12):1443\u20138. https:\/\/doi.org\/10.1080\/14712598.2022.2093106.","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"1662_CR4","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/jdv.15653","volume":"33","author":"RB Crowley","year":"2019","unstructured":"Crowley RB, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676\u201384. https:\/\/doi.org\/10.1111\/jdv.15653.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1662_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170\u20133. https:\/\/doi.org\/10.7861\/clinmed.2021-0257.","journal-title":"Clin Med (Lond)"},{"issue":"3","key":"1662_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. https:\/\/doi.org\/10.1111\/dth.12589.","journal-title":"Dermatol Ther"},{"key":"1662_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000232309","volume":"38","author":"K Kragballe","year":"2009","unstructured":"Kragballe K. Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm\/soles and nails. Curr Probl Dermatol. 2009;38:160\u201371. https:\/\/doi.org\/10.1159\/000232309.","journal-title":"Curr Probl Dermatol"},{"issue":"1","key":"1662_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13555-023-01065-0","volume":"14","author":"ME Horner","year":"2024","unstructured":"Horner ME, Orroth KK, Ma J, Duan Y, Cordey M. Redefining disease severity with special area involvement and reflecting on treatment patterns in a real-world psoriasis population. Dermatol Ther (Heidelb). 2024;14(1):187\u201399. https:\/\/doi.org\/10.1007\/s13555-023-01065-0.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1662_CR9","doi-asserted-by":"publisher","first-page":"247553032413020","DOI":"10.1177\/24755303241302070","volume":"21","author":"B Strober","year":"2024","unstructured":"Strober B, Zhong Y, Sima A, et al. Criteria for identifying candidates for systemic psoriasis treatment in the real world: application of the International Psoriasis Council guidelines in patients in North America. J Psoriasis Psoriatic Arthritis. 2024;21:24755303241302070. https:\/\/doi.org\/10.1177\/24755303241302070.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"1662_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/PTT.S85330","volume":"6","author":"K Blakely","year":"2016","unstructured":"Blakely K, Gooderham M. Management of scalp psoriasis: current perspectives. Psoriasis (Auckl). 2016;6:33\u201340. https:\/\/doi.org\/10.2147\/PTT.S85330.","journal-title":"Psoriasis (Auckl)"},{"issue":"1","key":"1662_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2287401","volume":"35","author":"B Strober","year":"2024","unstructured":"Strober B, Callis Duffin K, Lebwohl M, et al. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the Corevitas psoriasis registry. J Dermatolog Treat. 2024;35(1):2287401. https:\/\/doi.org\/10.1080\/09546634.2023.2287401.","journal-title":"J Dermatolog Treat"},{"key":"1662_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/PTT.S169389","volume":"8","author":"EJ Yang","year":"2018","unstructured":"Yang EJ, Beck KM, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl). 2018;8:41\u20137. https:\/\/doi.org\/10.2147\/PTT.S169389.","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"1662_CR13","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaad.2008.11.910","volume":"60","author":"E Farley","year":"2009","unstructured":"Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60(6):1024\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2008.11.910.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1662_CR14","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1503a5318","volume":"15","author":"M Esposito","year":"2025","unstructured":"Esposito M, Praino E, Micali G, Musumeci ML, Borgia F, Bianchi L. Clinical and ultrasonographic assessment of nail psoriasis: a comprehensive study. Dermatol Pract Concept. 2025;15(3):5318. https:\/\/doi.org\/10.5826\/dpc.1503a5318.","journal-title":"Dermatol Pract Concept"},{"issue":"7","key":"1662_CR15","doi-asserted-by":"publisher","first-page":"T703","DOI":"10.1016\/j.ad.2025.05.010","volume":"116","author":"M Ribera","year":"2025","unstructured":"Ribera M, Ferr\u00e1ndiz C, Daud\u00e9n E, et al. [Translated article] Expert recommendations on topical therapy for psoriasis from the Spanish Psoriasis Working Group (GPS). Actas Dermosifiliogr. 2025;116(7):T703\u201330. https:\/\/doi.org\/10.1016\/j.ad.2025.05.010.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"1662_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jaad.2019.01.072","volume":"81","author":"D Rigopoulos","year":"2019","unstructured":"Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. J Am Acad Dermatol. 2019;81(1):228\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2019.01.072.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1662_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/14712598.2025.2519525","volume":"25","author":"M Megna","year":"2025","unstructured":"Megna M, Lauletta G, D\u2019Agostino M, et al. Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use. Expert Opin Biol Ther. 2025;25(7):711\u201329. https:\/\/doi.org\/10.1080\/14712598.2025.2519525.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"1662_CR18","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40265-020-01357-1","volume":"80","author":"HA Blair","year":"2020","unstructured":"Blair HA. Risankizumab: a review in moderate to severe plaque psoriasis. Drugs. 2020;80(12):1235\u201345. https:\/\/doi.org\/10.1007\/s40265-020-01357-1.","journal-title":"Drugs"},{"issue":"12","key":"1662_CR19","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamadermatol.2020.3617","volume":"156","author":"M Augustin","year":"2020","unstructured":"Augustin M, Lambert J, Zema C, et al. Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol. 2020;156(12):1344\u201353. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3617.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1662_CR20","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s13555-025-01474-3","volume":"15","author":"B Strober","year":"2025","unstructured":"Strober B, Patel M, Kaldas MI, et al. Real-world skin clearance and quality of life with risankizumab in patients with psoriasis with moderate skin involvement and those eligible for systemic therapy per International Psoriasis Council classification. Dermatol Ther (Heidelb). 2025;15(9):2409\u201321. https:\/\/doi.org\/10.1007\/s13555-025-01474-3.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"1662_CR21","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s13555-024-01238-5","volume":"14","author":"KB Gordon","year":"2024","unstructured":"Gordon KB, Blauvelt A, Bachelez H, et al. Long-term safety of risankizumab in patients with psoriatic disease: a comprehensive analysis from clinical trials. Dermatol Ther (Heidelb). 2024;14(9):2523\u201338. https:\/\/doi.org\/10.1007\/s13555-024-01238-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1662_CR22","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s13555-023-01026-7","volume":"13","author":"BS Kim","year":"2023","unstructured":"Kim BS, Jo SJ, Youn S, et al. Five-year maintenance of clinical response and consistent safety profile for guselkumab in Asian patients with psoriasis from VOYAGE 1 and VOYAGE 2. Dermatol Ther (Heidelb). 2023;13(11):2721\u201337. https:\/\/doi.org\/10.1007\/s13555-023-01026-7.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"104","key":"1662_CR23","doi-asserted-by":"publisher","first-page":"18672","DOI":"10.2340\/actadv.v104.18672","volume":"4","author":"E Sonkoly","year":"2024","unstructured":"Sonkoly E, Maul JT, Megna M, et al. Guselkumab in patients with scalp psoriasis: a post hoc analysis of the VOYAGE 2 phase\u00a0III randomized clinical trial. Acta Derm Venereol. 2024;4(104):18672. https:\/\/doi.org\/10.2340\/actadv.v104.18672.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1662_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-023-00816-1","volume":"25","author":"L Puig","year":"2024","unstructured":"Puig L, Costanzo A, de Jong EMGJ, et al. Guselkumab-treated patients with plaque psoriasis who achieved complete skin clearance for \u2265156 consecutive weeks: a post-hoc analysis from the VOYAGE 1 clinical trial. Am J Clin Dermatol. 2024;25(2):315\u201325. https:\/\/doi.org\/10.1007\/s40257-023-00816-1.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1662_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2220447","volume":"34","author":"A Egeberg","year":"2023","unstructured":"Egeberg A, Jullien D, Du Jardin KG, Tha\u00e7i D. Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase\u00a03 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest. J Dermatolog Treat. 2023;34(1):2220447. https:\/\/doi.org\/10.1080\/09546634.2023.2220447.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1662_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14712598.2024.2325547","volume":"24","author":"P Dapavo","year":"2024","unstructured":"Dapavo P, Burlando M, Guarneri C, et al. Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden. Expert Opin Biol Ther. 2024;24(3):133\u20138. https:\/\/doi.org\/10.1080\/14712598.2024.2325547.","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"1662_CR27","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s13555-025-01442-x","volume":"15","author":"E Trovato","year":"2025","unstructured":"Trovato E, Bianchelli T, Odorici G, et al. Effectiveness of tildrakizumab 200\u00a0mg in moderate-to-severe plaque psoriasis: a multicenter real-world study analyzing patient outcomes by weight, PASI, BMI, and previous therapies. Dermatol Ther (Heidelb). 2025;15(7):1941\u201352. https:\/\/doi.org\/10.1007\/s13555-025-01442-x.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1662_CR28","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813\u201320. https:\/\/doi.org\/10.1080\/09546634.2022.2081655.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1662_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020495","volume":"13","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al. Effectiveness, tolerability, and drug survival of risankizumab in a real-world setting: a three-year retrospective multicenter study\u2014IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Clin Med. 2024;13(2):495. https:\/\/doi.org\/10.3390\/jcm13020495.","journal-title":"J Clin Med"},{"key":"1662_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1341708","volume":"14","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses \u2013 IL PSO (Italian landscape psoriasis). Front Immunol. 2024;14:1341708. https:\/\/doi.org\/10.3389\/fimmu.2023.1341708.","journal-title":"Front Immunol"},{"key":"1662_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19117","author":"M Dragotto","year":"2023","unstructured":"Dragotto M, Capalbo E, Cartocci A, et al. Real-life effectiveness of risankizumab according to body mass index: results of an Italian multicentre retrospective study. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19117.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1662_CR32","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s13555-025-01416-z","volume":"15","author":"M Valenti","year":"2025","unstructured":"Valenti M, Ibba L, Di Giulio S, et al. Optimizing tildrakizumab dosing in psoriasis: a 52-week multicenter retrospective study comparing 100\u00a0mg and 200\u00a0mg\u2014IL PSO (Italian Landscape Psoriasis). Dermatol Ther (Heidelb). 2025;15(6):1427\u201340. https:\/\/doi.org\/10.1007\/s13555-025-01416-z.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"1662_CR33","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s13555-025-01476-1","volume":"15","author":"M Valenti","year":"2025","unstructured":"Valenti M, Ibba L, Di Giulio S, et al. Guselkumab retention, effectiveness, and safety in psoriasis: a 260-week real-world multicenter retrospective study exploring the role of concomitant PsA\u2014IL PSO (Italian Landscape Psoriasis). Dermatol Ther (Heidelb). 2025;15(9):2423\u201337. https:\/\/doi.org\/10.1007\/s13555-025-01476-1.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"1662_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15506","volume":"35","author":"E Trovato","year":"2022","unstructured":"Trovato E, Cortonesi G, Orsini C, et al. Anti-IL23 for nail psoriasis in real life: results of efficacy and safety during a 52-week period. Dermatol Ther. 2022;35(7):e15506. https:\/\/doi.org\/10.1111\/dth.15506.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1662_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56719-8","volume":"16","author":"N Dand","year":"2025","unstructured":"Dand N, Stuart PE, Bowes J, et al. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. Nat Commun. 2025;16(1):2051. https:\/\/doi.org\/10.1038\/s41467-025-56719-8.","journal-title":"Nat Commun"},{"key":"1662_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15382","volume":"8","author":"LC Tsoi","year":"2017","unstructured":"Tsoi LC, Stuart PE, Tian C, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;8:15382. https:\/\/doi.org\/10.1038\/ncomms15382.","journal-title":"Nat Commun"},{"issue":"23","key":"1662_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316725","volume":"24","author":"VS Krishnan","year":"2023","unstructured":"Krishnan VS, K\u00f5ks S. Transcriptional landscape of repetitive elements in psoriatic skin from large cohort studies: relevance to psoriasis pathophysiology. Int J Mol Sci. 2023;24(23):16725. https:\/\/doi.org\/10.3390\/ijms242316725.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1662_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116130","volume":"23","author":"VS Krishnan","year":"2022","unstructured":"Krishnan VS, K\u00f5ks S. Transcriptional basis of psoriasis from large scale gene expression studies: the importance of moving towards a precision medicine approach. Int J Mol Sci. 2022;23(11):6130. https:\/\/doi.org\/10.3390\/ijms23116130.","journal-title":"Int J Mol Sci"},{"issue":"22","key":"1662_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216344","volume":"24","author":"VM Stacey","year":"2023","unstructured":"Stacey VM, K\u00f5ks S. Genome-wide differential transcription of long noncoding RNAs in psoriatic skin. Int J Mol Sci. 2023;24(22):16344. https:\/\/doi.org\/10.3390\/ijms242216344.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1662_CR40","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/j.1365-2133.2006.07731.x","volume":"156","author":"K Kingo","year":"2007","unstructured":"Kingo K, M\u00f6ssner R, K\u00f5ks S, et al. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol. 2007;156(4):646\u201352. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07731.x.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01662-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:06:37Z","timestamp":1774371997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01662-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1662"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01662-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alessandra Cartocci, Francesca Gaiani, Francesco Messina, Luca Mastorino, Nicole Macagno, Andrea Carugno, Marco Campoli, Maria Concetta Fargnoli, Viviana Lora, Agnese Rossi, Helena Gioacchini, Luca Potestio, Giovanni Marco D\u2019Agostino, Martina Maurelli, Giampiero Girolomoni, Marco Romanelli, Valentina Dini, Francesco Loconsole, Francesca Satolli, Gianluca Pagnanelli, Claudia Lasagni, Andrea Michelerio, Martina Dragotto, Piergiorgio Malagoli, Nicola Zerbinati, Diego Orsini, Matteo Megna, Tommaso Bianchelli, Antonio Costanzo, Simone Ribero, Alessandra Narcisi, Marco Manfredini, Davide Strippoli, Clara De Simone, Franco Rongioletti, Santo Mercuri, Massimiliano Nicolini, Giancarlo Lazzaro Danzuso, Andrea Altomare, Carlo Carrera, Aldo Cuccia, Claudio Guarneri, Claudia Giofre', Alessandro Borghi, Anna Scuderi, Nicoletta Bernardini, Federico Bardazzi, Francesco Cona, Alexandra Brunasso Vannetti, Annunziata Raimondo, Vito Di Lernia, Carmen Fiorella, Pietro Morrone, Alessandra Capo, Giulia Rech, have nothing to disclose. Anna Campanati is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Anna Campanati was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Diego Orsini is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Diego Orsini was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review board approval was exempted, as the study protocol did not deviate from standard clinical practice. All patients received guselkumab, risankizumab, and tildrakizumab 200\u00a0mg, as per good clinical practice. All included patients provided written consent for retrospective study of data collected during routine clinical practice (demographics and clinical scores). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}